CRS conducts in-house Pharmacokinetic and Pharmacodynamic (PK/PD) studies within its dedicated early-phase clinical research unit, enabling detailed characterization of a drug’s behavior and biological effects in humans. Our unit is designed to support intensive sampling, frequent assessments, and complex study designs required to generate high-quality PK and PD data.

We support a broad range of PK/PD studies in healthy volunteers and selected patient populations, including dose-proportionality, food-effect, drug–drug interaction, and mechanism-of-action assessments. Protocol execution focuses on precise timing of sample collection, standardized procedures, and controlled study conditions to minimize variability and ensure data reliability.

CRS manages all clinical aspects of in-house PK/PD studies, from subject recruitment and screening through dosing, inpatient and outpatient visits, and specialized assessments. Our teams are experienced in managing dense PK sampling schedules alongside PD endpoints such as biomarkers, physiological measurements, and functional assessments, ensuring accurate linkage between exposure and effect.

PK/PD activities are closely coordinated with bioanalytical, data management, and statistical functions to support timely data availability and integrated analysis. Continuous medical oversight and real-time review of emerging results allow for informed operational decisions during study conduct.

By combining dedicated infrastructure, experienced early-phase teams, and integrated clinical services, CRS delivers PK/PD studies that provide meaningful insight into drug behavior and support informed dose selection and development strategy.

‍